Palvella Therapeutics, Inc. (PVLA)
123.46
+3.08
(+2.56%)
USD |
NASDAQ |
Apr 02, 16:00
124.00
+0.54
(+0.44%)
After-Hours: 04:12
Palvella Therapeutics Enterprise Value : 1.728B for April 2, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ligand Pharmaceuticals, Inc. | 3.705B |
| Gossamer Bio, Inc. | 152.81M |
| Agenus, Inc. | 453.02M |
| Novavax, Inc. | 786.69M |
| Regeneron Pharmaceuticals, Inc. | 74.90B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.71M |
| Total Expenses (Quarterly) | 12.71M |
| EPS Diluted (Quarterly) | -1.082 |
| Earnings Yield | -3.00% |
| Normalized Earnings Yield | -2.972 |